A clinical trial update dated August 7, 2026 reports on a study relevant to degarelix, an approved compound used in prostate cancer treatment contexts. The trial, registered as NCT04633252, is titled "A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer."
The study is listed as Phase I/II. Its current status is recruiting. This means the trial is actively enrolling participants as of the update date.
The trial evaluates PDS01ADC in combination with docetaxel and abiraterone in adults with metastatic castration sensitive prostate cancer, as well as PDS01ADC with docetaxel in castration resistant prostate cancer. No results or outcome data have been reported as part of this update. The status reflects only the recruitment stage of the trial, not any efficacy or safety findings.
Readers should note that this update reflects trial administrative status only. No conclusions about treatment effects can be drawn from a recruiting status. Further updates may be issued as the trial progresses through its phases.
For more background on degarelix, readers can consult the compound overview.